Insilico Medicine Announces Novel 3CL Protease Inhibitor Precl...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
NEW YORK, May 25, 2022 /PRNewswire-AsiaNet/ -- -Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir.-The candidate is intended to be used for the treatment of SARS-CoV-2 and its v...
Authors: LATEST ASIANET NEWS RELEASES